Rofecoxib and Cardiovascular Adverse Events in Adjuvant Treatment of Colorectal Cancer - Kerr, David J; Dunn, Janet A; Langman, Michael J; Smith, Justine L; Midgley, Rachel S.J; Stanley, Andrew; Stokes, Joanne C; Julier, Patrick; Iveson, Claire; Duvvuri, Ravi; McConkey, Christopher C (The New England journal of medicine, 2007)
Keywords: Adenoma - prevention & control; Adenoma - surgery; Aged; Biological and medical sciences; Cancer therapies; Cardiovascular Diseases - chemically induced; Cardiovascular Diseases - epidemiology; Cardiovascular Diseases - mortality; Chemotherapy, Adjuvant; Colorectal cancer; Colorectal Neoplasms - prevention & control; Colorectal Neoplasms - surgery; Cyclooxygenase 2 Inhibitors - adverse effects; Cyclooxygenase 2 Inhibitors - therapeutic use; Disease prevention; Drug therapy; Female; Follow-Up Studies; Gastroenterology. Liver. Pancreas. Abdomen; General aspects; Humans; Incidence; Lactones - adverse effects; Lactones - therapeutic use; Male; Medical sciences; Middle Aged; Neoplasm Recurrence, Local - prevention & control; Risk; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus; Sulfones - adverse effects; Sulfones - therapeutic use; Surgery; Tumors; Prostaglandin-endoperoxide synthase; Rectal disease; Rofecoxib; Enzyme; Toxicity; Colorectal cancer; Adjuvant treatment; Enzyme inhibitor; Cardiovascular disease; Cyclooxygenase 2 inhibitor; Malignant tumor; Colonic disease; Non steroidal antiinflammatory agent; Medicine; Secondary effect; Digestive diseases; Intestinal disease; Complication; Oxidoreductases